Marzena Mackowiak

Dr. Marzena Mackowiak

Laboratory of Pharmacology and Brain Biostructure, Department of Pharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, 31-343 Krakow, Poland
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AWAdam Wojtas
Adam Wojtas
ABAgnieszka Bysiek
Agnieszka Bysiek
AWAgnieszka Wawrzczak-Bargiela
Agnieszka Wawrzczak-Bargiela
ZSZuzanna Szych
Zuzanna Szych
IMIwona Majcher-Maślanka
Iwona Majcher-Maślanka
KGKrystyna Gołembiowska
Krystyna Gołembiowska
Clinical studies provide evidence that ketamine and psilocybin could be used as fast-acting antidepressants, though their mechanisms and toxicity are still not fully understood. To address this issue, we have examined the effect of a single administration of ketamine and psilocybin on the extracellular levels of neurotransmitters in the rat frontal cortex and reticular nucleus of the thalamus using microdialysis. The genotoxic effect and density of glutamate receptor proteins was measured with comet assay and Western blot, respectively. An open field test, light–dark box test and forced swim test were conducted to examine rat behavior 24 h after drug administration. Ketamine (10 mg/kg) and psilocybin (2 and 10 mg/kg) increased dopamine, serotonin, glutamate and GABA extracellular levels in the frontal cortex, while psilocybin also increased GABA in the reticular nucleus of the thalamus. Oxidative DNA damage due to psilocybin was observed in the frontal cortex and from both drugs in the hippocampus. NR2A subunit levels were increased after psilocybin (10 mg/kg). Behavioral tests showed no antidepressant or anxiolytic effects, and only ketamine suppressed rat locomotor activity. The observed changes in neurotransmission might lead to genotoxicity and increased NR2A levels, while not markedly affecting animal behavior.

1 July 2002 in Neuropharmacology
Verified
Journal Article
Closed access
MMMarzena Mackowiak
Marzena Mackowiak
MOMichael J O’neill
Michael J O’neill
CHCaroline A Hicks
Caroline A Hicks
DBDavid Bleakman
David Bleakman
PSPhil Skolnick
Phil Skolnick

1 October 2014 in Pharmacological Reports
Verified
Journal Article
Closed access
MMMarzena Mackowiak
Marzena Mackowiak
PMPatrycja Mordalska
Patrycja Mordalska
KWKrzysztof Wędzony
Krzysztof Wędzony

1 February 2009 in Neuroscience
Verified
Journal Article
Closed access
MMMarzena Mackowiak
Marzena Mackowiak
ACA. Chocyk
A. Chocyk
DDD. Dudys
D. Dudys
KWK. Wedzony
K. Wedzony

1 January 2018 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
EBEwelina Bator
Ewelina Bator
JLJoachim Latusz
Joachim Latusz
KWKrzysztof Wędzony
Krzysztof Wędzony
MMMarzena Mackowiak
Marzena Mackowiak

1 February 2014 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
MMMarzena Mackowiak
Marzena Mackowiak
EBEwelina Bator
Ewelina Bator
JLJoachim Latusz
Joachim Latusz
PMPatrycja Mordalska
Patrycja Mordalska
KWKrzysztof Wędzony
Krzysztof Wędzony